GlobeImmune to use grant for TB studies
Last Updated: 15:46 September 4, 2013
The Louisville-based drug research and development company is collaborating with Colorado State University professor Ian Orme on the project, which is funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the company said in a press statement.
Orme plans to test the Tarmogen research drug on animals, according to the press statement. In addition to treatment research, the testing could lead to more effective vaccines against tuberculosis as well, Orme said in the press statement. The U.S. Food and Drug Administration requires drug candidates to go through an extensive clinical trial process that can take up to 10 years to receive approval.
Tuberculosis infection causes more than 2 million deaths every year, which puts it in the rank of the top three infectious diseases causing death globally, along with HIV/AIDS and malaria. In addition, an estimated 2 billion people have been infected with tuberculosis, although 99 percent have immune systems that are able to battle the disease, according to the press statement. Of the 2 billion infections, more than 650,000 cases are multi-drug resistant, according to the press statement.
GlobeImmune received $17.5 million in venture capital funding in 2010 and $13 million in 2009. The company researches new drug candidates to treat cancer and infectious diseases, based on its Tarmogen research. Tarmogens activate the human body’s immune system by stimulating an immunity system, known as “T cell immunity.”
GlobeImmune is partnering with biopharmaceutical company Celgene Corp. in Summit, New Jersey, (Nasdaq: CELG) on research to commercialize drugs to treat cancer. The company also collaborates with Gilead Sciences Inc., in Foster City, California, (Nasdaq: GILD) to develop Tarmogen-based drug treatments for Hepatitis B infections.
More breaking news...
WhiteWave buying Earthbound Farm
Jobs grant will aid flood-impacted counties
Broomfield-based WhiteWave (NYSE: WWAV) said the deal is expected to close in the first
Job growth to continue in state next year
About 230 temporary workers will be hired to clean up and repair areas in